Last reviewed · How we verify
NCT03536494
Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron
NA trial testing Review the use of mirabegron and its discontinuation in Overactive Bladder Syndrome in 1,932 participants. Completed in 31 December 2017.
31 December 2017
Quick facts
| Lead sponsor | Catalan Institute of Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 1,932 |
| Start date | 1 January 2017 |
| Primary completion | 31 December 2017 |
| Estimated completion | 31 December 2017 |
Drugs / interventions tested
- Review the use of mirabegron and its discontinuation
Conditions studied
- Overactive Bladder Syndrome — all drugs for Overactive Bladder Syndrome →
Sponsor
Catalan Institute of Health
Who can join
18 and older, any sex, with Overactive Bladder Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was a multicentre, quasi-experimental design, controlled, before-and-after trial to estimate the effectiveness related to the review of mirabegron use and, if appropriate, its discontinuation. Intervention group: Patients with mirabegron prescription assigned to any of the 17 primary health care centers (PHC) located in the northern area of Barcelona. Control group: All the other patients assigned to any of the other 34 health care centers in Barcelona belonging to the Catalan Institut of Health (CIH). The structured intervention included initiatives with general practitioners and urologists/gynaecologists, management support from health care authorities, and monthly feed-back monitoring to general practitioners (GPs). The follow-up period was 12 months, from January 1st to December 31st, 2017.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effectiveness of an intervention to optimise the use of mirabegron for overactive bladder: a quasi-experimental study in primary care.
Fernández-Liz E, Tristante PV, Martínez AA, Colomer MEB, et al · · 2018 · cited 2× · PMID 30455222 · DOI 10.3399/bjgp18x699953
Verify or expand the search:
- PubMed search for NCT03536494
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overactive Bladder Syndrome
Currently open trials in the same condition.
- NCT05895045 — Yoga for Treatment of Overactive Bladder in Pediatric Patients · NA · recruiting
- NCT07081412 — Home-Based Transcutaneous Remotely Monitored Posterior Tibial Neuromodulation · NA · recruiting
- NCT07184307 — Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial · NA · recruiting
- NCT06546189 — Oral Lactobacillus Supplementation as Treatment for Overactive Bladder Syndrome: A Randomised Controlled Trial · NA · recruiting
- NCT06351683 — Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03536494 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Catalan Institute of Health
- Last refreshed: 7 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03536494.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing